医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

DUBLIN

Presbia PLC (NASDAQ: LENS), an ophthalmic device company and leader in near-vision restoration, announced that it will participate in the 20^th Annual Australasian Society of Cataract and Refractive Surgeons (AUSCRS) Conference. Dr. Wayne Crewe-Brown, one of the world’s most accomplished laser eye surgeons who also has the most experience performing the Presbia Flexivue Microlens™ implant in a commercial setting, will be conducting two educational presentations about the Presbia Flexivue Microlens, a proprietary optical lens implant and an innovative solution for treating the loss of near-vision. Dr. Crewe-Browne is also a member of Presbia’s Medical Advisory Board.

The annual AUSCRS conference, being held this year from July 20^th through the 23^rd at the Sheraton Mirage, Port Douglas in Queensland, Australia, presents up-to-date information on scientific developments within the field of cataract and refractive surgery, and is attended by AUSCRS members who are leading industry surgeons.

“Australia, New Zealand and South Korea are key markets for Presbia and we are very pleased that we will have the opportunity at the conference to expand the awareness of AUSCRS members of the Presbia Flexivue Microlens as safe, effective and the best surgical treatment for presbyopia,” said Todd Cooper. “This meeting will accelerate our expansion into these key countries and educate surgeons on the benefits of our surgical solution to reduce the need for reading glasses.”

Forward-Looking Statements

Information provided and statements contained in this press release that are not purely historical are forward-looking statements. Such forward-looking statements only speak as of the date of this press release and Presbia assumes no obligation to update the information included in this press release. Statements made in this press release that are forward-looking in nature may involve risks and uncertainties. Accordingly, readers are cautioned that any such forward-looking statements are not guarantees and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Although Presbia believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Unless otherwise required by law, Presbia also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made in this press release.

About Presbia

Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that has developed and is currently marketing the presbyopia-correcting Presbia Flexivue Microlens™, a miniature lens that is implanted in a corneal pocket created by a femtosecond laser. The Presbia Flexivue Microlens has received a CE mark for the European Economic Area, allowing the lens to be marketed in over 30 countries across Europe. A staged pivotal U.S. clinical trial for the Presbia Flexivue Microlens commenced in 2014.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160711005176/en/